569 related articles for article (PubMed ID: 26245900)
1. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.
Zaanan A; Okamoto K; Kawakami H; Khazaie K; Huang S; Sinicrope FA
J Biol Chem; 2015 Sep; 290(39):23838-49. PubMed ID: 26245900
[TBL] [Abstract][Full Text] [Related]
2. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
[TBL] [Abstract][Full Text] [Related]
3. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.
Hata AN; Yeo A; Faber AC; Lifshits E; Chen Z; Cheng KA; Walton Z; Sarosiek KA; Letai A; Heist RS; Mino-Kenudson M; Wong KK; Engelman JA
Cancer Res; 2014 Jun; 74(11):3146-56. PubMed ID: 24675361
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.
Wang CY; Guo ST; Wang JY; Liu F; Zhang YY; Yari H; Yan XG; Jin L; Zhang XD; Jiang CC
Mol Cancer Ther; 2016 Mar; 15(3):448-59. PubMed ID: 26832792
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor.
Kawabata T; Tanimura S; Asai K; Kawasaki R; Matsumaru Y; Kohno M
J Biol Chem; 2012 Mar; 287(13):10289-10300. PubMed ID: 22270368
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
[TBL] [Abstract][Full Text] [Related]
8. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
Pei XY; Dai Y; Tenorio S; Lu J; Harada H; Dent P; Grant S
Blood; 2007 Sep; 110(6):2092-101. PubMed ID: 17540843
[TBL] [Abstract][Full Text] [Related]
9. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA
Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849
[TBL] [Abstract][Full Text] [Related]
10. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.
Takezawa K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
Clin Cancer Res; 2011 Apr; 17(8):2140-8. PubMed ID: 21415216
[TBL] [Abstract][Full Text] [Related]
11. Combined MEK and BCL-2/X
Iavarone C; Zervantonakis IK; Selfors LM; Palakurthi S; Liu JF; Drapkin R; Matulonis UA; Hallberg D; Velculescu VE; Leverson JD; Sampath D; Mills GB; Brugge JS
Mol Cancer Ther; 2019 Mar; 18(3):642-655. PubMed ID: 30679390
[TBL] [Abstract][Full Text] [Related]
12. The Bcl-2 homology domain 3 (BH3)-only proteins Bim and bid are functionally active and restrained by anti-apoptotic Bcl-2 family proteins in healthy liver.
Kodama T; Hikita H; Kawaguchi T; Saito Y; Tanaka S; Shigekawa M; Shimizu S; Li W; Miyagi T; Kanto T; Hiramatsu N; Tatsumi T; Takehara T
J Biol Chem; 2013 Oct; 288(42):30009-30018. PubMed ID: 23986435
[TBL] [Abstract][Full Text] [Related]
13. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
Cragg MS; Jansen ES; Cook M; Harris C; Strasser A; Scott CL
J Clin Invest; 2008 Nov; 118(11):3651-9. PubMed ID: 18949058
[TBL] [Abstract][Full Text] [Related]
14. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.
Choudhary GS; Al-Harbi S; Mazumder S; Hill BT; Smith MR; Bodo J; Hsi ED; Almasan A
Cell Death Dis; 2015 Jan; 6(1):e1593. PubMed ID: 25590803
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells.
Abutin RM; Chen J; Lung TK; Lloyd JA; Sawyer ST; Harada H
Exp Hematol; 2009 Feb; 37(2):151-8. PubMed ID: 19100675
[TBL] [Abstract][Full Text] [Related]
16. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
[TBL] [Abstract][Full Text] [Related]
17. IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome.
Niss O; Sholl A; Bleesing JJ; Hildeman DA
J Allergy Clin Immunol; 2015 Mar; 135(3):762-70. PubMed ID: 25174872
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models.
Tan N; Wong M; Nannini MA; Hong R; Lee LB; Price S; Williams K; Savy PP; Yue P; Sampath D; Settleman J; Fairbrother WJ; Belmont LD
Mol Cancer Ther; 2013 Jun; 12(6):853-64. PubMed ID: 23475955
[TBL] [Abstract][Full Text] [Related]
19. Mutant B-RAF mediates resistance to anoikis via Bad and Bim.
Boisvert-Adamo K; Aplin AE
Oncogene; 2008 May; 27(23):3301-12. PubMed ID: 18246127
[TBL] [Abstract][Full Text] [Related]
20. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.
Kiyota M; Kuroda J; Yamamoto-Sugitani M; Shimura Y; Nakayama R; Nagoshi H; Mizutani S; Chinen Y; Sasaki N; Sakamoto N; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
Apoptosis; 2013 Nov; 18(11):1437-1446. PubMed ID: 23851982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]